Key clinical point: In patients with metastatic breast cancer (BC), germline BRCA1/2 mutation (gBRCAm) had a differential prognostic impact for triple-negative BC (TNBC) or hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) BC.

Major finding: Compared with gBRCA wild-type (WT) BC, gBRCAm BC showed comparable overall survival (OS) and first-line progression-free survival (PFS1) outcomes in the overall cohort of patients with metastatic BC (both P > .05), better OS (hazard ratio [HR] 0.76; P = .027) and PFS1 (HR 0.69; P = .001) in the TNBC subgroup, and worse PFS1 (HR 1.23; P = .024) in the HR+/HER2− BC subgroup.

Study details: Findings are from a retrospective cohort including 20,624 patients with newly diagnosed metastatic BC, of which 325 had gBRCAm, 1138 had gBRCA WT, and 19,161 had not tested for gBRCA.

Disclosures: This study was funded by an industrial consortium. Several authors declared receiving personal fees, grants, nonfinancial support, or travel support from several sources, including some of the companies in the consortium. Seventeen authors declared no conflicts of interest.

Source: Mailliez A et al. Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database. Int J Cancer. 2022 (Sep 26). Doi: 10.1002/ijc.34304

Key clinical point: In patients with metastatic breast cancer (BC), germline BRCA1/2 mutation (gBRCAm) had a differential prognostic impact for triple-negative BC (TNBC) or hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) BC.

Major finding: Compared with gBRCA wild-type (WT) BC, gBRCAm BC showed comparable overall survival (OS) and first-line progression-free survival (PFS1) outcomes in the overall cohort of patients with metastatic BC (both P > .05), better OS (hazard ratio [HR] 0.76; P = .027) and PFS1 (HR 0.69; P = .001) in the TNBC subgroup, and worse PFS1 (HR 1.23; P = .024) in the HR+/HER2− BC subgroup.

Study details: Findings are from a retrospective cohort including 20,624 patients with newly diagnosed metastatic BC, of which 325 had gBRCAm, 1138 had gBRCA WT, and 19,161 had not tested for gBRCA.

Disclosures: This study was funded by an industrial consortium. Several authors declared receiving personal fees, grants, nonfinancial support, or travel support from several sources, including some of the companies in the consortium. Seventeen authors declared no conflicts of interest.

Source: Mailliez A et al. Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database. Int J Cancer. 2022 (Sep 26). Doi: 10.1002/ijc.34304

Key clinical point: In patients with metastatic breast cancer (BC), germline BRCA1/2 mutation (gBRCAm) had a differential prognostic impact for triple-negative BC (TNBC) or hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) BC.

Major finding: Compared with gBRCA wild-type (WT) BC, gBRCAm BC showed comparable overall survival (OS) and first-line progression-free survival (PFS1) outcomes in the overall cohort of patients with metastatic BC (both P > .05), better OS (hazard ratio [HR] 0.76; P = .027) and PFS1 (HR 0.69; P = .001) in the TNBC subgroup, and worse PFS1 (HR 1.23; P = .024) in the HR+/HER2− BC subgroup.

Study details: Findings are from a retrospective cohort including 20,624 patients with newly diagnosed metastatic BC, of which 325 had gBRCAm, 1138 had gBRCA WT, and 19,161 had not tested for gBRCA.

Disclosures: This study was funded by an industrial consortium. Several authors declared receiving personal fees, grants, nonfinancial support, or travel support from several sources, including some of the companies in the consortium. Seventeen authors declared no conflicts of interest.

Source: Mailliez A et al. Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database. Int J Cancer. 2022 (Sep 26). Doi: 10.1002/ijc.34304

Key clinical point: Patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC) who relapsed after prior (neo)adjuvant trastuzumab (T) treatment benefitted from dual blockade with pertuzumab + trastuzumab (P + T) in routine clinical practice.

Major finding: The median progression-free survival was 18.8 months, with comparable outcomes observed in patients with hormone receptor (HR)-positive vs HR-negative BC (18.2 vs 19.4 months) and with visceral vs non-visceral metastasis (18.0 vs 20.5 months). No new safety signals were reported, and 6.1% of patients reported fatal serious adverse events.

Study details: Findings are from the observational, noninterventional, HELENA study including 126 patients with HER2+ metastatic BC who relapsed after prior (neo)adjuvant T treatment and received first-line P + T + chemotherapy.

Disclosures: This study was funded by Roche Pharma AG. Some authors declared receiving personal fees, grants, honoraria, or consulting fees from several sources, and one author declared being an employee and holding stocks in Roche Pharma.

Source: Thill M et al. Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: Results from a German non-interventional study (NIS) HELENA (NCT01777958). Breast Cancer Res Treat. 2022 (Sep 12). Doi: 10.1007/s10549-022-06710-4

Key clinical point: Patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC) who relapsed after prior (neo)adjuvant trastuzumab (T) treatment benefitted from dual blockade with pertuzumab + trastuzumab (P + T) in routine clinical practice.

Major finding: The median progression-free survival was 18.8 months, with comparable outcomes observed in patients with hormone receptor (HR)-positive vs HR-negative BC (18.2 vs 19.4 months) and with visceral vs non-visceral metastasis (18.0 vs 20.5 months). No new safety signals were reported, and 6.1% of patients reported fatal serious adverse events.

Study details: Findings are from the observational, noninterventional, HELENA study including 126 patients with HER2+ metastatic BC who relapsed after prior (neo)adjuvant T treatment and received first-line P + T + chemotherapy.

Disclosures: This study was funded by Roche Pharma AG. Some authors declared receiving personal fees, grants, honoraria, or consulting fees from several sources, and one author declared being an employee and holding stocks in Roche Pharma.

Source: Thill M et al. Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: Results from a German non-interventional study (NIS) HELENA (NCT01777958). Breast Cancer Res Treat. 2022 (Sep 12). Doi: 10.1007/s10549-022-06710-4

Key clinical point: Patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC) who relapsed after prior (neo)adjuvant trastuzumab (T) treatment benefitted from dual blockade with pertuzumab + trastuzumab (P + T) in routine clinical practice.

Major finding: The median progression-free survival was 18.8 months, with comparable outcomes observed in patients with hormone receptor (HR)-positive vs HR-negative BC (18.2 vs 19.4 months) and with visceral vs non-visceral metastasis (18.0 vs 20.5 months). No new safety signals were reported, and 6.1% of patients reported fatal serious adverse events.

Study details: Findings are from the observational, noninterventional, HELENA study including 126 patients with HER2+ metastatic BC who relapsed after prior (neo)adjuvant T treatment and received first-line P + T + chemotherapy.

Disclosures: This study was funded by Roche Pharma AG. Some authors declared receiving personal fees, grants, honoraria, or consulting fees from several sources, and one author declared being an employee and holding stocks in Roche Pharma.

Source: Thill M et al. Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: Results from a German non-interventional study (NIS) HELENA (NCT01777958). Breast Cancer Res Treat. 2022 (Sep 12). Doi: 10.1007/s10549-022-06710-4

Key clinical point: The combination of apatinib and vinorelbine lowered the risk for disease progression and was well tolerated in patients with metastatic triple-negative breast cancer (TNBC) who had failed first or second-line treatment.

Major finding: There was a significant improvement in progression-free survival with apatinib + vinorelbine vs only vinorelbine (hazard ratio 1.82; P = .026). Leukopenia (42.4% vs 40.6%) and granulocytopenia (57.6% vs 31.3%) were the most frequent grade 3-4 hematologic adverse events in the apatinib + vinorelbine vs vinorelbine group.

Study details: Findings are from the phase 2, NAN study including 66 patients with recurrent or metastatic TNBC who had failed first or second-line treatment and were randomly assigned to receive apatinib + vinorelbine or vinorelbine.

Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.

Source: Li DD et al. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: The NAN trial. NPJ Breast Cancer. 2022;8:110 (Sep 20). Doi: 10.1038/s41523-022-00462-6

Key clinical point: The combination of apatinib and vinorelbine lowered the risk for disease progression and was well tolerated in patients with metastatic triple-negative breast cancer (TNBC) who had failed first or second-line treatment.

Major finding: There was a significant improvement in progression-free survival with apatinib + vinorelbine vs only vinorelbine (hazard ratio 1.82; P = .026). Leukopenia (42.4% vs 40.6%) and granulocytopenia (57.6% vs 31.3%) were the most frequent grade 3-4 hematologic adverse events in the apatinib + vinorelbine vs vinorelbine group.

Study details: Findings are from the phase 2, NAN study including 66 patients with recurrent or metastatic TNBC who had failed first or second-line treatment and were randomly assigned to receive apatinib + vinorelbine or vinorelbine.

Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.

Source: Li DD et al. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: The NAN trial. NPJ Breast Cancer. 2022;8:110 (Sep 20). Doi: 10.1038/s41523-022-00462-6

Key clinical point: The combination of apatinib and vinorelbine lowered the risk for disease progression and was well tolerated in patients with metastatic triple-negative breast cancer (TNBC) who had failed first or second-line treatment.

Major finding: There was a significant improvement in progression-free survival with apatinib + vinorelbine vs only vinorelbine (hazard ratio 1.82; P = .026). Leukopenia (42.4% vs 40.6%) and granulocytopenia (57.6% vs 31.3%) were the most frequent grade 3-4 hematologic adverse events in the apatinib + vinorelbine vs vinorelbine group.

Study details: Findings are from the phase 2, NAN study including 66 patients with recurrent or metastatic TNBC who had failed first or second-line treatment and were randomly assigned to receive apatinib + vinorelbine or vinorelbine.

Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.

Source: Li DD et al. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: The NAN trial. NPJ Breast Cancer. 2022;8:110 (Sep 20). Doi: 10.1038/s41523-022-00462-6

Key clinical point: Switch to fulvestrant + palbociclib from aromatase inhibitor (AI) + palbociclib improved progression-free survival (PFS) without increasing toxicity in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) and high levels of ESR1 mutation in the blood (bESR1^mut).

Major finding: Median PFS improved significantly in the fulvestrant + palbociclib vs AI + palbociclib group (stratified hazard ratio 0.61; 2-sided P = .0040). The rates of most common grade ≥3 adverse events, such as neutropenia (44.3% and 41.7%, respectively) and lymphopenia (4.5% and 3.6%, respectively), were similar in the fulvestrant + palbociclib and AI + palbociclib groups.

Study details: Findings are from the phase 3, PADA-1 trial including 172 patients with ER+HER2− advanced BC, rising bESR1^mut, and no synchronous disease progression with first-line AI + palbociclib who were randomly assigned to continue AI + palbociclib or switch to fulvestrant + palbociclib.

Disclosures: This study was funded by Pfizer. Some authors declared receiving grants, honoraria, consulting fees, or travel support, or having other ties with several sources, including Pfizer.

Source: Bidard FC et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): A randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022 (Sep 29). Doi: 10.1016/S1470-2045(22)00555-1

Key clinical point: Switch to fulvestrant + palbociclib from aromatase inhibitor (AI) + palbociclib improved progression-free survival (PFS) without increasing toxicity in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) and high levels of ESR1 mutation in the blood (bESR1^mut).

Major finding: Median PFS improved significantly in the fulvestrant + palbociclib vs AI + palbociclib group (stratified hazard ratio 0.61; 2-sided P = .0040). The rates of most common grade ≥3 adverse events, such as neutropenia (44.3% and 41.7%, respectively) and lymphopenia (4.5% and 3.6%, respectively), were similar in the fulvestrant + palbociclib and AI + palbociclib groups.

Study details: Findings are from the phase 3, PADA-1 trial including 172 patients with ER+HER2− advanced BC, rising bESR1^mut, and no synchronous disease progression with first-line AI + palbociclib who were randomly assigned to continue AI + palbociclib or switch to fulvestrant + palbociclib.

Disclosures: This study was funded by Pfizer. Some authors declared receiving grants, honoraria, consulting fees, or travel support, or having other ties with several sources, including Pfizer.

Source: Bidard FC et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): A randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022 (Sep 29). Doi: 10.1016/S1470-2045(22)00555-1

Key clinical point: Switch to fulvestrant + palbociclib from aromatase inhibitor (AI) + palbociclib improved progression-free survival (PFS) without increasing toxicity in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) and high levels of ESR1 mutation in the blood (bESR1^mut).

Major finding: Median PFS improved significantly in the fulvestrant + palbociclib vs AI + palbociclib group (stratified hazard ratio 0.61; 2-sided P = .0040). The rates of most common grade ≥3 adverse events, such as neutropenia (44.3% and 41.7%, respectively) and lymphopenia (4.5% and 3.6%, respectively), were similar in the fulvestrant + palbociclib and AI + palbociclib groups.

Study details: Findings are from the phase 3, PADA-1 trial including 172 patients with ER+HER2− advanced BC, rising bESR1^mut, and no synchronous disease progression with first-line AI + palbociclib who were randomly assigned to continue AI + palbociclib or switch to fulvestrant + palbociclib.

Disclosures: This study was funded by Pfizer. Some authors declared receiving grants, honoraria, consulting fees, or travel support, or having other ties with several sources, including Pfizer.

Source: Bidard FC et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): A randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022 (Sep 29). Doi: 10.1016/S1470-2045(22)00555-1

Key clinical point: Patients with atopic dermatitis (AD) have a 50% higher chance of developing alcohol use disorder (AUD) than people without AD and should be screened when appropriate.

Major finding: Patients with AD had a significantly higher chance of developing AUD (odds ratio 1.50; P < .001) than controls without AD.

Study details: Findings are from the All of Us cohort including 11,752 patients with AD and 47,008 matched controls.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Fan R et al. Alcohol use disorder among adults with atopic dermatitis: A case-control study in the All of Us research program. J Am Acad Dermatol. 2022 (Sep 20). Doi: 10.1016/j.jaad.2022.09.015

Key clinical point: Patients with atopic dermatitis (AD) have a 50% higher chance of developing alcohol use disorder (AUD) than people without AD and should be screened when appropriate.

Major finding: Patients with AD had a significantly higher chance of developing AUD (odds ratio 1.50; P < .001) than controls without AD.

Study details: Findings are from the All of Us cohort including 11,752 patients with AD and 47,008 matched controls.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Fan R et al. Alcohol use disorder among adults with atopic dermatitis: A case-control study in the All of Us research program. J Am Acad Dermatol. 2022 (Sep 20). Doi: 10.1016/j.jaad.2022.09.015

Key clinical point: Patients with atopic dermatitis (AD) have a 50% higher chance of developing alcohol use disorder (AUD) than people without AD and should be screened when appropriate.

Major finding: Patients with AD had a significantly higher chance of developing AUD (odds ratio 1.50; P < .001) than controls without AD.

Study details: Findings are from the All of Us cohort including 11,752 patients with AD and 47,008 matched controls.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Fan R et al. Alcohol use disorder among adults with atopic dermatitis: A case-control study in the All of Us research program. J Am Acad Dermatol. 2022 (Sep 20). Doi: 10.1016/j.jaad.2022.09.015

Key clinical point: The presence of dampness and mold at home affected offspring health outcomes negatively by increasing the prevalence of atopic dermatitis (AD).

Major finding: AD was associated with visible mold (odds ratio [OR] 1.35; P  =  .001) and dampness/mold at home between the first and second follow-up (OR 1.18; P  =  .008) and during both follow-up periods (OR 1.38; P < .001).

Study details: Findings are from the Respiratory Health in Northern Europe study including 17,881 offspring aged ≤30 years who had undergone two follow-up investigations every 10 years. Of these, 17.3% had developed AD.

Disclosures: This study was supported by the Icelandic Research Council and other sources. The authors declared no conflicts of interest.

Source: Wang J et al. Asthma, allergic rhinitis and atopic dermatitis in association with home environment—The RHINE study. Sci Total Environ. 2022;853:158609 (Sep 8). Doi: 10.1016/j.scitotenv.2022.158609

Key clinical point: The presence of dampness and mold at home affected offspring health outcomes negatively by increasing the prevalence of atopic dermatitis (AD).

Major finding: AD was associated with visible mold (odds ratio [OR] 1.35; P  =  .001) and dampness/mold at home between the first and second follow-up (OR 1.18; P  =  .008) and during both follow-up periods (OR 1.38; P < .001).

Study details: Findings are from the Respiratory Health in Northern Europe study including 17,881 offspring aged ≤30 years who had undergone two follow-up investigations every 10 years. Of these, 17.3% had developed AD.

Disclosures: This study was supported by the Icelandic Research Council and other sources. The authors declared no conflicts of interest.

Source: Wang J et al. Asthma, allergic rhinitis and atopic dermatitis in association with home environment—The RHINE study. Sci Total Environ. 2022;853:158609 (Sep 8). Doi: 10.1016/j.scitotenv.2022.158609

Key clinical point: The presence of dampness and mold at home affected offspring health outcomes negatively by increasing the prevalence of atopic dermatitis (AD).

Major finding: AD was associated with visible mold (odds ratio [OR] 1.35; P  =  .001) and dampness/mold at home between the first and second follow-up (OR 1.18; P  =  .008) and during both follow-up periods (OR 1.38; P < .001).

Study details: Findings are from the Respiratory Health in Northern Europe study including 17,881 offspring aged ≤30 years who had undergone two follow-up investigations every 10 years. Of these, 17.3% had developed AD.

Disclosures: This study was supported by the Icelandic Research Council and other sources. The authors declared no conflicts of interest.

Source: Wang J et al. Asthma, allergic rhinitis and atopic dermatitis in association with home environment—The RHINE study. Sci Total Environ. 2022;853:158609 (Sep 8). Doi: 10.1016/j.scitotenv.2022.158609

Key clinical point: Lactobacillus rhamnosus, with or without other probiotics, reduced the incidence risk for atopic dermatitis (AD) in children when administered to mothers and infants in the perinatal period.

Major finding: The risk of developing AD was significantly reduced at 2 years (risk ratio [RR] 0.60; P < .00001) and 6-7 years (RR  0.62; P < .00001) with L. rhamnosus or L. rhamnosus + other probiotic strains.

Study details: Findings are from a meta-analysis of 11 randomized controlled trials that reported the incidence of AD after oral administration of L. rhamnosus or L. rhamnasos + other probiotics during pregnancy and post-pregnancy in mothers and infants.

Disclosures: J Voigt received partial funding. The authors declared serving as an evidence assessment expert or an executive for Lil Mixins, a manufacturer of probiotic supplements.

Source: Voigt J and Lele M. Lactobacillus rhamnosus used in the perinatal period for the prevention of atopic dermatitis in infants: A systematic review and meta-analysis of randomized trials. Am J Clin Dermatol. 2022;23:801–811 (Sep 26). Doi: 10.1007/s40257-022-00723-x

Key clinical point: Lactobacillus rhamnosus, with or without other probiotics, reduced the incidence risk for atopic dermatitis (AD) in children when administered to mothers and infants in the perinatal period.

Major finding: The risk of developing AD was significantly reduced at 2 years (risk ratio [RR] 0.60; P < .00001) and 6-7 years (RR  0.62; P < .00001) with L. rhamnosus or L. rhamnosus + other probiotic strains.

Study details: Findings are from a meta-analysis of 11 randomized controlled trials that reported the incidence of AD after oral administration of L. rhamnosus or L. rhamnasos + other probiotics during pregnancy and post-pregnancy in mothers and infants.

Disclosures: J Voigt received partial funding. The authors declared serving as an evidence assessment expert or an executive for Lil Mixins, a manufacturer of probiotic supplements.

Source: Voigt J and Lele M. Lactobacillus rhamnosus used in the perinatal period for the prevention of atopic dermatitis in infants: A systematic review and meta-analysis of randomized trials. Am J Clin Dermatol. 2022;23:801–811 (Sep 26). Doi: 10.1007/s40257-022-00723-x

Key clinical point: Lactobacillus rhamnosus, with or without other probiotics, reduced the incidence risk for atopic dermatitis (AD) in children when administered to mothers and infants in the perinatal period.

Major finding: The risk of developing AD was significantly reduced at 2 years (risk ratio [RR] 0.60; P < .00001) and 6-7 years (RR  0.62; P < .00001) with L. rhamnosus or L. rhamnosus + other probiotic strains.

Study details: Findings are from a meta-analysis of 11 randomized controlled trials that reported the incidence of AD after oral administration of L. rhamnosus or L. rhamnasos + other probiotics during pregnancy and post-pregnancy in mothers and infants.

Disclosures: J Voigt received partial funding. The authors declared serving as an evidence assessment expert or an executive for Lil Mixins, a manufacturer of probiotic supplements.

Source: Voigt J and Lele M. Lactobacillus rhamnosus used in the perinatal period for the prevention of atopic dermatitis in infants: A systematic review and meta-analysis of randomized trials. Am J Clin Dermatol. 2022;23:801–811 (Sep 26). Doi: 10.1007/s40257-022-00723-x

Key clinical point: Patients with atopic dermatitis (AD) who received adjunctive allergen immunotherapy (AIT) reported improvements in disease severity and quality of life despite an increase in the rate of adverse events (AE).

Major finding: AIT vs no AIT improved disease severity (risk ratio [RR] 1.53; 95% CI 1.31-1.78) and the Dermatology Life Quality Index by at least 4 points (RR 1.44; 95% CI 1.03-2.01). The rates of local (RR 1.65; 95% CI 1.48-1.64) and systemic (RR 1.37; 95% CI 1.15-1.64) AE were higher with AIT vs placebo.

Study details: Findings are from a meta-analysis of 23 randomized controlled trials including 1957 adult and pediatric patients with moderate-to-severe AD who were randomly assigned to adjunctive AIT (subcutaneous or sublingual immunotherapy) or no AIT (placebo or standard care).

Disclosures: This study was supported by the American Academy of Allergy, Asthma, & Immunology and other sources. The authors declared no conflicts of interest.

Source: Yepes-Nuñez JJ et al. Allergen immunotherapy for atopic dermatitis: A systematic review and meta-analysis of benefits and harms. J Allergy Clin Immunol. 2022 (Sep 30). Doi: 10.1016/j.jaci.2022.09.020

Key clinical point: Patients with atopic dermatitis (AD) who received adjunctive allergen immunotherapy (AIT) reported improvements in disease severity and quality of life despite an increase in the rate of adverse events (AE).

Major finding: AIT vs no AIT improved disease severity (risk ratio [RR] 1.53; 95% CI 1.31-1.78) and the Dermatology Life Quality Index by at least 4 points (RR 1.44; 95% CI 1.03-2.01). The rates of local (RR 1.65; 95% CI 1.48-1.64) and systemic (RR 1.37; 95% CI 1.15-1.64) AE were higher with AIT vs placebo.

Study details: Findings are from a meta-analysis of 23 randomized controlled trials including 1957 adult and pediatric patients with moderate-to-severe AD who were randomly assigned to adjunctive AIT (subcutaneous or sublingual immunotherapy) or no AIT (placebo or standard care).

Disclosures: This study was supported by the American Academy of Allergy, Asthma, & Immunology and other sources. The authors declared no conflicts of interest.

Source: Yepes-Nuñez JJ et al. Allergen immunotherapy for atopic dermatitis: A systematic review and meta-analysis of benefits and harms. J Allergy Clin Immunol. 2022 (Sep 30). Doi: 10.1016/j.jaci.2022.09.020

Key clinical point: Patients with atopic dermatitis (AD) who received adjunctive allergen immunotherapy (AIT) reported improvements in disease severity and quality of life despite an increase in the rate of adverse events (AE).

Major finding: AIT vs no AIT improved disease severity (risk ratio [RR] 1.53; 95% CI 1.31-1.78) and the Dermatology Life Quality Index by at least 4 points (RR 1.44; 95% CI 1.03-2.01). The rates of local (RR 1.65; 95% CI 1.48-1.64) and systemic (RR 1.37; 95% CI 1.15-1.64) AE were higher with AIT vs placebo.

Study details: Findings are from a meta-analysis of 23 randomized controlled trials including 1957 adult and pediatric patients with moderate-to-severe AD who were randomly assigned to adjunctive AIT (subcutaneous or sublingual immunotherapy) or no AIT (placebo or standard care).

Disclosures: This study was supported by the American Academy of Allergy, Asthma, & Immunology and other sources. The authors declared no conflicts of interest.

Source: Yepes-Nuñez JJ et al. Allergen immunotherapy for atopic dermatitis: A systematic review and meta-analysis of benefits and harms. J Allergy Clin Immunol. 2022 (Sep 30). Doi: 10.1016/j.jaci.2022.09.020

Key clinical point: Rate of COVID-19 hospitalizations varied by treatment modalities in patients with atopic dermatitis (AD) who received immunomodulatory drugs.

Major finding: Rate of COVID-19 hospitalizations was higher among patients who received topical treatment vs dupilumab (adjusted odds ratio [aOR] 4.99; 95% CI 1.4-20.84) or combination therapy with systemic corticosteroids vs monotherapy with nonsteroidal immunosuppressants (aOR 45.75; 95% CI 4.54-616.22).

Study details: Findings are from the SECURE-AD registry including 442 patients with AD and a diagnosis of COVID-19 who received immunomodulatory treatments.

Disclosures: This study is funded by the University of Amsterdam and other sources. Some authors declared serving as employees or receiving grants, consulting fees, honoraria, or travel support from several sources.

Source: Musters AH et al. The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry. J Eur Acad Dermatol Venereol. 2022 (Sep 28). Doi: 10.1111/jdv.18613

Key clinical point: Rate of COVID-19 hospitalizations varied by treatment modalities in patients with atopic dermatitis (AD) who received immunomodulatory drugs.

Major finding: Rate of COVID-19 hospitalizations was higher among patients who received topical treatment vs dupilumab (adjusted odds ratio [aOR] 4.99; 95% CI 1.4-20.84) or combination therapy with systemic corticosteroids vs monotherapy with nonsteroidal immunosuppressants (aOR 45.75; 95% CI 4.54-616.22).

Study details: Findings are from the SECURE-AD registry including 442 patients with AD and a diagnosis of COVID-19 who received immunomodulatory treatments.

Disclosures: This study is funded by the University of Amsterdam and other sources. Some authors declared serving as employees or receiving grants, consulting fees, honoraria, or travel support from several sources.

Source: Musters AH et al. The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry. J Eur Acad Dermatol Venereol. 2022 (Sep 28). Doi: 10.1111/jdv.18613

Key clinical point: Rate of COVID-19 hospitalizations varied by treatment modalities in patients with atopic dermatitis (AD) who received immunomodulatory drugs.

Major finding: Rate of COVID-19 hospitalizations was higher among patients who received topical treatment vs dupilumab (adjusted odds ratio [aOR] 4.99; 95% CI 1.4-20.84) or combination therapy with systemic corticosteroids vs monotherapy with nonsteroidal immunosuppressants (aOR 45.75; 95% CI 4.54-616.22).

Study details: Findings are from the SECURE-AD registry including 442 patients with AD and a diagnosis of COVID-19 who received immunomodulatory treatments.

Disclosures: This study is funded by the University of Amsterdam and other sources. Some authors declared serving as employees or receiving grants, consulting fees, honoraria, or travel support from several sources.

Source: Musters AH et al. The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry. J Eur Acad Dermatol Venereol. 2022 (Sep 28). Doi: 10.1111/jdv.18613

Key clinical point: Tralokinumab, with or without topical corticosteroids (TCS), demonstrated significant efficacy in reducing disease severity and was well-tolerated in North American patients with moderate-to-severe atopic dermatitis (AD).

Major finding: At week 16, a significantly higher proportion of patients receiving tralokinumab vs placebo achieved ≥75% improvement in the Eczema Area and Severity Index in ECZTRA 1/2 (40.1% vs 19.4%; P < .001) and ECZTRA 3 (58.1% vs 37.0%; P  =  .012) studies. Tralokinumab with or without TCS was also well-tolerated in the North American population.

Study details: Findings are from a post hoc analysis of three tralokinumab trials including patients with moderate-to-severe AD who were randomly assigned to receive tralokinumab or placebo, both with TCS as needed (ECZTRA 3; n = 160) or without TCS (ECZTRA 1 and 2; n = 559).

Disclosures: The ECZTRA trials were sponsored by LEO Pharma A/S. Three authors declared being current or former employees of LEO Pharma. The other authors reported ties with several sources, including LEO Pharma.

Source: Blauvelt A et al. Tralokinumab efficacy and safety, with or without topical corticosteroids, in North American adults with moderate-to-severe atopic dermatitis: A subanalysis of phase 3 trials ECZTRA 1, 2, and 3. Dermatol Ther (Heidelb). 2022 (Sep 24). Doi: 10.1007/s13555-022-00805-y

Key clinical point: Tralokinumab, with or without topical corticosteroids (TCS), demonstrated significant efficacy in reducing disease severity and was well-tolerated in North American patients with moderate-to-severe atopic dermatitis (AD).

Major finding: At week 16, a significantly higher proportion of patients receiving tralokinumab vs placebo achieved ≥75% improvement in the Eczema Area and Severity Index in ECZTRA 1/2 (40.1% vs 19.4%; P < .001) and ECZTRA 3 (58.1% vs 37.0%; P  =  .012) studies. Tralokinumab with or without TCS was also well-tolerated in the North American population.

Study details: Findings are from a post hoc analysis of three tralokinumab trials including patients with moderate-to-severe AD who were randomly assigned to receive tralokinumab or placebo, both with TCS as needed (ECZTRA 3; n = 160) or without TCS (ECZTRA 1 and 2; n = 559).

Disclosures: The ECZTRA trials were sponsored by LEO Pharma A/S. Three authors declared being current or former employees of LEO Pharma. The other authors reported ties with several sources, including LEO Pharma.

Source: Blauvelt A et al. Tralokinumab efficacy and safety, with or without topical corticosteroids, in North American adults with moderate-to-severe atopic dermatitis: A subanalysis of phase 3 trials ECZTRA 1, 2, and 3. Dermatol Ther (Heidelb). 2022 (Sep 24). Doi: 10.1007/s13555-022-00805-y

Key clinical point: Tralokinumab, with or without topical corticosteroids (TCS), demonstrated significant efficacy in reducing disease severity and was well-tolerated in North American patients with moderate-to-severe atopic dermatitis (AD).

Major finding: At week 16, a significantly higher proportion of patients receiving tralokinumab vs placebo achieved ≥75% improvement in the Eczema Area and Severity Index in ECZTRA 1/2 (40.1% vs 19.4%; P < .001) and ECZTRA 3 (58.1% vs 37.0%; P  =  .012) studies. Tralokinumab with or without TCS was also well-tolerated in the North American population.

Study details: Findings are from a post hoc analysis of three tralokinumab trials including patients with moderate-to-severe AD who were randomly assigned to receive tralokinumab or placebo, both with TCS as needed (ECZTRA 3; n = 160) or without TCS (ECZTRA 1 and 2; n = 559).

Disclosures: The ECZTRA trials were sponsored by LEO Pharma A/S. Three authors declared being current or former employees of LEO Pharma. The other authors reported ties with several sources, including LEO Pharma.

Source: Blauvelt A et al. Tralokinumab efficacy and safety, with or without topical corticosteroids, in North American adults with moderate-to-severe atopic dermatitis: A subanalysis of phase 3 trials ECZTRA 1, 2, and 3. Dermatol Ther (Heidelb). 2022 (Sep 24). Doi: 10.1007/s13555-022-00805-y